Apraglutide
A long-acting GLP-2 analogue in development for short bowel syndrome with intestinal failure.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Clinical Trials
Investigational; not FDA-approved for the uses discussed.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A long-acting GLP-2 analogue in development for short bowel syndrome with intestinal failure.
Investigational; not FDA-approved for the uses discussed.
A positive study and a confirmatory program do not establish FDA approval or benefits outside short bowel syndrome.
Why It's Being Studied
- Short bowel syndrome
- Parenteral-support reduction
Mechanism of Action
GLP-2 signalling is intended to increase intestinal absorptive capacity and reduce dependence on parenteral support.
GLP-2 signalling is intended to increase intestinal absorptive capacity and reduce dependence on parenteral support. A positive study and a confirmatory program do not establish FDA approval or benefits outside short bowel syndrome.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Short bowel syndrome
- Parenteral-support reduction
- Subcutaneous clinical research
Evidence Summary
The STARS program reported reductions in parenteral support; a confirmatory phase 3 STARS-2 program was planned in 2026.
Higher tiers carry more weight. Filled tiers have evidence for Apraglutide; tap to read it.
- The STARS program reported reductions in parenteral support; a confirmatory phase 3 STARS-2 program was planned in 2026.
1 cited sources.
- Clinical trial1
Human clinical evidence
- The STARS program reported reductions in parenteral support; a confirmatory phase 3 STARS-2 program was planned in 2026.
Reported Adverse Events in Research
- Intestinal-growth and fluid-balance safety require evaluation; GLP-2 class concerns are not automatically proven apraglutide harms.
Limitations of Current Evidence
- A positive study and a confirmatory program do not establish FDA approval or benefits outside short bowel syndrome.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Apraglutide | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Clinical Trials | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Clinical trial
Apraglutide — clinical trial